Cargando…

Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly replaced the Delta variant as a dominating SARS-CoV-2 variant because of natural selection, which favors the variant with higher infectivity and stronger vaccine breakthrough ability. Omicron has three li...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiahui, Wei, Guo-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887081/
https://www.ncbi.nlm.nih.gov/pubmed/35233567
http://dx.doi.org/10.21203/rs.3.rs-1362445/v1
_version_ 1784660816807591936
author Chen, Jiahui
Wei, Guo-Wei
author_facet Chen, Jiahui
Wei, Guo-Wei
author_sort Chen, Jiahui
collection PubMed
description The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly replaced the Delta variant as a dominating SARS-CoV-2 variant because of natural selection, which favors the variant with higher infectivity and stronger vaccine breakthrough ability. Omicron has three lineages or subvariants, BA.1 (B.1.1.529.1), BA.2 (B.1.1.529.2), and BA.3 (B.1.1.529.3). Among them, BA.1 is the currently prevailing subvariant. BA.2 shares 32 mutations with BA.1 but has 28 distinct ones. BA.3 shares most of its mutations with BA.1 and BA.2 except for one. BA.2 is found to be able to alarmingly reinfect patients originally infected by Omicron BA.1. An important question is whether BA.2 or BA.3 will become a new dominating “variant of concern”. Currently, no experimental data has been reported about BA.2 and BA.3. We construct a novel algebraic topology-based deep learning model trained with tens of thousands of mutational and deep mutational data to systematically evaluate BA.2’s and BA.3’s infectivity, vaccine breakthrough capability, and antibody resistance. Our comparative analysis of all main variants namely, Alpha, Beta, Gamma, Delta, Lambda, Mu, BA.1, BA.2, and BA.3, unveils that BA.2 is about 1.5 and 4.2 times as contagious as BA.1 and Delta, respectively. It is also 30% and 17-fold more capable than BA.1 and Delta, respectively, to escape current vaccines. Therefore, we project that Omicron BA.2 is on its path to becoming the next dominating variant. We forecast that like Omicron BA.1, BA.2 will also seriously compromise most existing mAbs, except for sotrovimab developed by GlaxoSmithKline.
format Online
Article
Text
id pubmed-8887081
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Journal Experts
record_format MEDLINE/PubMed
spelling pubmed-88870812022-03-02 Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant Chen, Jiahui Wei, Guo-Wei Res Sq Article The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly replaced the Delta variant as a dominating SARS-CoV-2 variant because of natural selection, which favors the variant with higher infectivity and stronger vaccine breakthrough ability. Omicron has three lineages or subvariants, BA.1 (B.1.1.529.1), BA.2 (B.1.1.529.2), and BA.3 (B.1.1.529.3). Among them, BA.1 is the currently prevailing subvariant. BA.2 shares 32 mutations with BA.1 but has 28 distinct ones. BA.3 shares most of its mutations with BA.1 and BA.2 except for one. BA.2 is found to be able to alarmingly reinfect patients originally infected by Omicron BA.1. An important question is whether BA.2 or BA.3 will become a new dominating “variant of concern”. Currently, no experimental data has been reported about BA.2 and BA.3. We construct a novel algebraic topology-based deep learning model trained with tens of thousands of mutational and deep mutational data to systematically evaluate BA.2’s and BA.3’s infectivity, vaccine breakthrough capability, and antibody resistance. Our comparative analysis of all main variants namely, Alpha, Beta, Gamma, Delta, Lambda, Mu, BA.1, BA.2, and BA.3, unveils that BA.2 is about 1.5 and 4.2 times as contagious as BA.1 and Delta, respectively. It is also 30% and 17-fold more capable than BA.1 and Delta, respectively, to escape current vaccines. Therefore, we project that Omicron BA.2 is on its path to becoming the next dominating variant. We forecast that like Omicron BA.1, BA.2 will also seriously compromise most existing mAbs, except for sotrovimab developed by GlaxoSmithKline. American Journal Experts 2022-02-23 /pmc/articles/PMC8887081/ /pubmed/35233567 http://dx.doi.org/10.21203/rs.3.rs-1362445/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Chen, Jiahui
Wei, Guo-Wei
Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant
title Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant
title_full Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant
title_fullStr Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant
title_full_unstemmed Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant
title_short Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant
title_sort omicron ba.2 (b.1.1.529.2): high potential to becoming the next dominating variant
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887081/
https://www.ncbi.nlm.nih.gov/pubmed/35233567
http://dx.doi.org/10.21203/rs.3.rs-1362445/v1
work_keys_str_mv AT chenjiahui omicronba2b115292highpotentialtobecomingthenextdominatingvariant
AT weiguowei omicronba2b115292highpotentialtobecomingthenextdominatingvariant